Abstract: The disclosure provides a nanoemulsion including an oil phase containing at least one cannabinoid and a water phase; wherein at least one of the oil phase and the water phase includes one or more emulsifying agents; and wherein the zeta potential of the nanoemulsion is less than about ?10 mV. Further provided are processes for preparing such nanoemulsions.

Abstract: The present invention is directed to a liposome composition for use in the peritoneal dialysis of patients suffering from endogenous or exogenous toxicopathies, wherein the pH within the liposomes differs from the pH in the intraperitoneal cavity and wherein the pH within the liposome results in a liposome-encapsulated charged toxin. The invention also relates to a pharmaceutical composition comprising said liposomes. A further aspect of the present invention relates to a method of treating patients suffering from endogenous or exogenous toxicopathies, preferably selected from drug, metabolite, pesticide, insecticide, toxin, and chemical warfare toxicopathies, more preferably hyperammonemia, comprising the step of administering liposomes of the invention in a therapeutically effective amount into the peritoneal space of a patient in need thereof. Next to human, the present invention is particularly suitable to veterinary aspects.

Abstract: A nanocarrier containing a combination of bioactive agents is provided. The nanocarrier allows for targeted delivery of the agents to cancer cells with minimized side effect.

Abstract: Provided herein are compositions with enhanced sweetness or reduced caloric content per weight when compared to the sweetener carbohydrate or sweetener polyol component thereof, and methods for the preparation thereof.

Abstract: The present invention relates to an in-vivo bulking agent which can be used as a medicinal agent for prevention or treatment of at least one disease selected from the group consisting of urinary incontinence, fecal incontinence, and gastroesophageal reflux or as a filler for use in a plastic surgery procedure, and to a preparation method therefor. The in-vivo bulking agent can exhibit a bulking effect when injected into the body and particularly, is highly biocompatible because a first composition in which silicone particles are coated with a zwitterionic polymer having a surfactant property is introduced into a second composition, whereby the bulking agent can inhibit inflammatory reactions in vivo.

Abstract: The invention relates to a new method for the formulation of oily substances, and to powders and solid dosage forms obtainable thereof. The process comprises a step of spray-drying of an oil-in-water emulsion comprising an octenyl succinate starch and a maltodextrin.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: The present invention relates to a composite preparation in a core tablet form, composed of an inner core containing rabeprazole as an effective ingredient; an outer layer portion including the bilayer structure of a sustained release layer and an immediate release layer and containing mosapride as an effective ingredient. The core tablet composite preparation according to the present invention is characterized by exerting sufficient pharmacological activity of rabeprazole and mosapride even upon administration of one tablet once a day.

Abstract: The present invention provides for a method of treatment of IgA nephropathy, which method comprises: (i) identifying a pharmaceutically acceptable composition intended to treat IgA nephropathy comprising budesonide and one or more pharmaceutically-acceptable excipients that provide for a modified release of said budesonide after administration to the gastrointestinal tract, which composition fulfils the following requirements in a standard in vitro USP<711>/Ph.Eur. 2.9.3 dissolution test using a dissolution apparatus according to Apparatus 2 (Paddle Apparatus) of said test; (a) the composition fulfils the requirement that no more than about 10% of the budesonide is released into the dissolution medium within about 120 minutes, when the dissolution medium is aqueous and has a pH of about 1.

Abstract: The present disclosure relates to orally available stabilized supplement-containing articles (e.g., softgels). The stabilized supplement may be a probiotic, and may contain a stabilizing component derived from chocolate. The present disclosure also relates to methods of making such stabilized articles.

Abstract: An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain a solid core containing the L-carnitine, and an enteric coating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body.

Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.

Abstract: A benefit agent delivery system whereby benefit agents can be released over a period of time and/or a variety of different benefit agents can be delivered from the same system and/or different concentrations of benefit agents can be delivered from the same system. The benefit agent delivery system includes a plurality of microcells, wherein the microcells are filled with a formulation comprising a benefit agent and an organic solvent. The microcells include an opening, and the opening is spanned by a porous diffusion layer. Different microcells may be loaded with different benefit agents, thereby providing a mechanism to deliver different, complimentary, or incompatible benefit agents.

Abstract: A wound dressing includes: a structural material formed into a dressing; at least one immunomodulatory agent associated with the dressing; and a growth factor associated with the dressing. A wound dressing kit includes: a structural material formed into a wound dressing; an immunomodulatory agent; and a growth factor composition, wherein the structural material contains the immunomodulatory agent and/or the immunomodulatory agent in a separate composition. A method of treating a wound in a tissue includes: applying an immunomodulatory agent to the wound; applying a wound dressing to the wound; and allowing the wound to heal with the immunomodulatory agent and wound dressing. The application of a growth factor can be before, during and/or after applying the wound dressing to the wound.

Abstract: The invention relates to portable bag for sterilizing an object accommodated therein. The portable bag comprises a flexible body defining an internal space for accommodating the object; a plurality of ultraviolet (UV) radiation emitting means arranged at opposing internal walls of the flexible body; wherein the flexible body comprises one or more layers of fabric material, with one layer of the one or more layers forming the internal walls comprising a reflective fabric material adapted to reflect ultraviolet (UV) radiation emitted from the UV radiation emitting means and UV radiation reflected from the object. The invention further relates to a method of manufacturing said portable bag.

Abstract: Provided herein are various enhanced techniques for ultraviolet decontamination via emission of ultraviolet radiation and tracking emission exposure. An example method includes obtaining an emission characteristic for a radiation source. The method also includes capturing a depth map of a scene comprised of one or more objects and processing the depth map and an emission characteristic to determine an indication of exposure levels of the one or more objects to radiation emitted by the radiation source. An exposure visualization is generated based at least on the indication of exposure levels and displaying the exposure visualization.

Abstract: A lighting and sanitization device, comprises: a first light source emitting violet light having a wavelength between 380 and 430 nm; a second light source emitting white light; a third light source emitting lime light having a peak wavelength between 535 and 545 nm.

Abstract: An ultraviolet (“UV”) emission device may emit energy towards a movable surface of a conveyor system. A housing of the UV emission device may attach to a frame of the conveyor system. A lateral edge of the housing may extend across the moveable surface. The housing and a portion of the moveable surface may be inclined with respect to the frame. A barrier bracket of the UV emission device may support an absorptive barrier along the lateral edge, the absorptive barrier configured to contact the moveable surface. In a first position of the barrier bracket, the absorptive barrier contacts the moveable surface and the barrier bracket activates an interlock switch. In a second position of the barrier bracket, the barrier bracket deactivates the interlock switch. Responsive to deactivation of the interlock switch, a controller may provide a control signal to decrease power to the UV energy emission element.

Abstract: An UV disinfection system (200) may feature a chamber (207) with internal spherical reflective surfaces (208) to evenly reflect UV radiation from all angles to direct the UV radiation to all surface area of the object inside the chamber to disinfect object utilizing UV radiation under controlled time. An object (215) to be disinfected may reside within the chamber (207) on a UV transparent rack or shelf (214). The spherical reflective surfaces may be fashioned by placing such surfaces on a polyhedral internal structure or making the internal chamber spherical in and of itself (208). Multiple UV sources (209a), (209b) may also be utilized.

Abstract: The present invention provides a method for reprocessing single-use medical devices. The method can include removing a coating from a single-use medical device, validating the removal of the coating, cleaning the single-use medical device, and applying a new coating to the single-use medical device.

Abstract: A method of disinfecting a surface that is contaminated with a virus or suspected of contamination with a virus, including: producing a reactive gas by forming a high-voltage cold plasma (HVCP) from a working gas with a dielectric barrier discharge (DBD) system at a voltage of 20 kV to 150 kV; transporting the reactive gas at least 1 meter away from the HVCP; followed by contacting the surface with the reactive gas.

Abstract: The present invention is directed to a hemostatic material comprising a compacted, hemostatic aggregates of cellulosic fibers. In some aspects, the hemostatic material further includes additives, such as carboxymethyl cellulose (CMC) or other polysaccharides, calcium salts, anti-infective agents, hemostasis promoting agents, gelatin, collagen, or combinations thereof. In another aspect, the present invention is directed to a method of making the hemostatic materials described above by compacting a cellulosic-based material into hemostatic aggregates. In another aspect, the present invention is directed to a method of treating a wound by applying hemostatic materials described above onto and/or into the wound of a patient.

Abstract: According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a wound dressing is provided comprising a scaffold coated with a biologically active composition comprising a lipoic acid derivative. In a further embodiment, a system is provided for treating a tissue site of a patient, the system comprising a reduced-pressure source to supply reduced pressure, a manifold to distribute reduced pressure to a tissue site and a scaffold coated with a biologically active composition comprising a lipoic acid derivative. Methods for producing such a system and scaffold are also disclosed.

Abstract: Resorbable implants comprising poly(butylene succinate) and copolymers thereof have been developed. The implants are preferably sterilized, and contain less than 20 endotoxin units per device as determined by the limulus amebocyte lysate (LAL) assay, and are particularly suitable for use in procedures where prolonged strength retention is necessary, and can include one or more bioactive agents. The implants may be made from fibers and meshes of poly(butylene succinate) and copolymers thereof, or by 3d printing, and the fibers may be oriented. Coverings and receptacles made from forms of poly(butylene succinate) and copolymers thereof have also been developed for use with cardiac rhythm management devices and other implantable devices. These coverings and receptacles may be used to hold, or partially/fully cover, devices such as pacemakers and neurostimulators.

Abstract: The invention includes compositions including magnesium-lithium alloys containing various alloying elements for medical implant devices. The devices are constructed of the compositions or have applied thereto a coating formed therefrom. Within the structure of the magnesium-lithium alloy, there is a co-existence of alpha and beta phases. The invention also includes methods of preparing the magnesium-lithium alloys and articles, such as medical implant devices, for use in medical applications, including orthopedic, dental, craniofacial and cardiovascular surgery.

Abstract: Biomaterials, implants made therefrom, methods of making the biomaterial and implants, methods of promoting bone or wound healing in a mammal by administering the biomaterial or implant to the mammal, and kits that include such biomaterials, implants, or components thereof. The biomaterials may include demineralized cortical fibers, which help to promote bone repair.

Abstract: A method of producing an injectable gel product is provided, comprising (a) cross-linking a first glycosaminoglycan (GAG) with a first crosslinking agent to produce a gel, wherein the charging ratio of crosslinking agent to disaccharide unit is below 0.15; (b) preparing particles of the gel; (c) mixing the glycosaminoglycan (GAG) gel particles with a second GAG to provide a mixture; (d) cross-linking the mixture with a second crosslinking agent to obtain cross-linking between the GAGs of the second, outer phase, thereby providing a gel having a first, inner phase of the cross-linked GAG gel particles, embedded in a gel of the second GAG outer phase; and (e) preparing injectable particles, each such particle containing a plurality of the cross-linked GAG gel particles of the first, inner phase. An injectable gel product, an aqueous composition, and a pre-filled syringe as also provided.

Abstract: An electrically conductive hyaluronic acid-based hydrogel is disclosed that is a crosslinked porous scaffold having a graphene-based material encapsulated or in contact within the porous scaffold. The graphene-based material includes one or more of graphene oxide foam, reduced graphene oxide foam, nanoplatelets, nanoparticles, or fibers. The porous scaffold may be formed over an implanted bioelectronic device such as a microelectrode array having a plurality of electrodes. The porous scaffold may also be used to control the differentiation of cells including Neural Stem/Progenitor Cells (NS/PCs).

Abstract: Biodegradable antimicrobial films are provided that are solid at room temperature and substantially liquefy in situ after implantation into a mammal, such as a human patient. Methods of using the films to cover a medical device, such as a breast implant, prior to insertion into a subject are also provided.

Abstract: Compositions for forming porous materials and three-dimensional objects, including fibers, films and coatings made from the materials are provided. Also provided are methods for forming the porous objects from the compositions. The compositions include a solvent, a polymer binder that is soluble in the solvent, and solid particles that are insoluble in the solvent. The solid particles include water-soluble salt particles that can be selectively dissolved from objects made from the compositions to render the resulting structures porous.

Abstract: Disclosed herein is a device comprising a PHA based copolymer layer comprising at least one of an electrospun ribbon of fibers of a polyhydroxyalkanoate based copolymer or the polarized polymeric composition obtained by the process of claim 1, wherein the layer is configured to exhibit one or more of a piezoelectric effect, a pyroelectric effect and a ferroelectric effect, wherein each of the electrospun ribbon of fibers and the polarized polymeric composition comprises a ?-form of the PHA based copolymer present in an amount of from about 10% to about 99%, as measured by x-ray diffraction. The device can be configured for use as a sensor, a actuator, a nanomotor, or a biobattery.

Abstract: Various aspects of the present invention provide compositions and implantable devices including a water-insoluble therapeutic agent solubilized in a matrix of a gallate-containing compound. Other aspects provide methods of manufacturing and using such compositions and devices.

Abstract: A volatile composition dispenser and methods of volatilizing a volatile composition in the air are provided. The volatile composition dispenser includes one or more reservoirs, with each reservoir containing a volatile composition. Each reservoir has one or more delivery engines disposed in fluid communication with the volatile composition in the reservoir. Each delivery engine is in fluid communication with an evaporative surface. One or more evaporative assistance elements are disposed adjacent to the evaporative surface(s). A method of volatilizing the volatile composition(s) includes operating the evaporative assistance elements with varying energy over a total emission program, including energy boost periods, and extended emission periods of decreased or maintained energy.

Abstract: Cartridge for volatile substances in the liquid state, such as insecticides or fragrances, of the type including a tray-shaped container closed on one side with a multilayer film, said multilayer film consisting of at least one internal vapour permeable membrane and one external vapour barrier layer. Directing/assisting means are provided, adapted to direct/assist the removal of just a first portion of the external vapour barrier layer—in the form of notches, weakening lines or strengthening lines—along a desired partition line, for cartridge activation.

Abstract: A deodorization module includes a housing having a bar securing member and a substrate securing member, and formed of a reflective material, wherein each of the bar securing member and the substrate securing member protrudes inward from an inner side surface of the housing and has a groove. A photocatalyst bar is disposed such that air introduced into the housing passes through the photocatalyst bar. A light source module including a light source substrate and an ultraviolet (UV) light source is disposed on a first surface of the light source substrate, wherein the light source module is configured to emit light toward the photocatalyst bar. An external guide protrudes outward around an outer periphery of the housing.

Abstract: A blood component collection cassette that can trap a foreign object such as a blood-coagulated clot from blood components to be returned to a blood donor and a manufacturing method of the blood component collection cassette are provided. A sheet-shaped filter member (60) is arranged on a flow path (42) in a cassette main body (40) of a blood component collection cassette (28). A first tube (66) and a second tube (68) are arranged in the cassette main body (40). An inner space (51) of a filter housing unit (54a) is separated by the filter member (60) into a first space (51a) on the side of the first tube (66) and a second space (51b) on the side of the second tube (68).

Abstract: A medical treatment machine, such as a home dialysis machine, can receive prescription parameters that define parameters of a medical treatment to be administered to a patient. A medical prescription is entered by a clinician into a clinical information system (CIS) that calls a system to evaluate the compatibility of the entered prescription by transmitting the prescription parameters to a server that has access to a database of medical devices and their operational parameters. The server compares the treatment parameters of the medical prescription to the operational parameters of the medical device and generates a prescription compatibility response indicting if the treatment parameters of the medical prescription can be executed by the medical device. The server returns to the CIS the prescription compatibility response to allow the prescription, e.g. in a digital or program form, to be securely transmitted or delivered via a connected health system to the medical device.

Abstract: Absolute blood volume in dialysis patients is a useful patient attribute to know for dialysis treatment, diagnosis, adjustments, etc. In some cases, it is difficult or impossible to directly determine absolute blood volume. Estimating absolute blood volume may be used to overcome the inability to directly determine the absolute blood volume. Estimating absolute blood volume may include obtaining a series of measurements of hemoconcentration of a patient over a time period, and estimating parameters for a physiological model based on the series of measurements. The absolute blood volume of the patient may be determined using the physiological model.

Abstract: Dialyzer systems can consolidate multiple technologies and functionalities of blood treatment systems in a significantly integrated fashion. For example, this disclosure describes dialyzer systems that include a magnetically driven and magnetically levitating pump rotor integrated into the dialyzer. Such a dialyzer can be used with treatment modules that include a magnetic field-generating pump drive unit. In some embodiments, the dialyzers include pressure sensor chambers with flexible membranes with which corresponding pressure transducers of the treatment modules can interface to detect arterial and/or venous pressures.

Abstract: A fluid treatment plant has a filter module including at least a first filter and a second filter connected in series and connectable to a supply of fluid. A pump is fluidly connected to the filter module and a controller with a fluid quality sensor is connected to detect a quality of the fluid between the first filter and the second filter. A filter module detector is connected to the controller configured to uniquely detect a filter module connected to the pump, and the controller is controls the pump responsively to a signal from the fluid quality sensor and the module detector. The controller is configured to continue pumping based on output of the quality sensor and/or based on output from the filter module detector.

Abstract: An adjusting device for a pressure detector that is capable of arbitrarily adjusting the initial position of a membrane member is provided. An adjusting device for a pressure detector includes a control unit that sequentially executes a first step in which a predetermined adjusting pressure is generated in a first zone by activating a pump with the first zone being closed by the closing of an electromagnetic valve, and a second step in which a gas-phase portion, the first zone, and a second zone are combined into a closed space by disabling the closing of the electromagnetic valve; and an adjusting-pressure-acquiring unit that acquires the adjusting pressure to be generated in the first step, the adjusting pressure being acquired in accordance with a relationship between a pressure and a capacity of the first zone in the first step and a pressure and a capacity of the combination of the gas-phase portion, the first zone, and the second zone in the second step.

Abstract: A dialysis machine configured to carry out a method and a method for draining an extracorporeal fluid circuit utilizing a dialysis machine, wherein the dialysis machine is connected to a dialyzer and said extracorporeal fluid circuit, said extracorporeal fluid circuit comprising an arterial line connectable to a patient, for drawing blood from the patient and a venous line connectable to the patient for returning blood to the patient, the method comprising: after treatment termination from said extracorporeal fluid circuit draining remaining fluid from said extracorporeal fluid circuit through the dialyzer.

Abstract: A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject.

Abstract: A wound dressing apparatus includes a wound dressing member dimensioned for positioning relative to a wound bed. The wound dressing member including an internal vacuum reservoir and has a port in communication with the vacuum reservoir for applying subatmospheric pressure to the vacuum reservoir to facilitate removal of fluid from the wound bed. The wound dressing member includes a visual pressure indicator associated therewith for indicating a level of pressure within the vacuum reservoir. The visual pressure indicator includes color indicia having a plurality of colors corresponding to a condition of the pressure within the vacuum reservoir. The wound dressing member includes a lower absorbent member positionable adjacent the wound bed and an upper member which at least partially defines the vacuum reservoir. At least one of the top member and the lower absorbent member has the visual pressure indicator mounted thereto.

Abstract: A chest drainage system including a collection device configured to receive fluid from the pleural cavity of a patient. A sensor is included to detect a pressure differential in the fluid. A display is configured to display a trend in occurrences of changes in pressure of the fluid over time in predetermined time increments based on a number of detections of pressure differentials that exceed a predetermined pressure differential during each of the predetermined time increments. The trend is correlative to the percentage of time that the patient is deemed to have an air leak in the pleural cavity in the predetermined time increments. The trend is derived from a ratio of the quantity of respiratory cycles of the patient for which the predetermined pressure differential is detected (QRCleak) in the predetermined time increments to the total quantity of respiratory cycles of the patient in respective predetermined time increments (QRCtotal).

Abstract: A system for delivering reduced pressure and irrigation fluid to a wound site. The system includes a primary pressure source for delivering reduced pressure through a first lumen, a secondary pressure source for delivering secondary pressure through a second lumen, and an irrigation fluid source. A valve system is operable to selectively couple the secondary pressure source to the second lumen for delivering the secondary pressure to a wound site and selectively couple the fluid source to the second lumen for delivering the irrigation fluid to the wound site.

Abstract: A catheter or shaft, such as a distal access support or aspiration catheter, is provided that is configured to be advanced at least partially within a patient. The catheter or shaft may include a flexible and hollow shaft including a proximal end and a distal end. The flexible and hollow shaft may include a slotted portion with a plurality of slotted openings, the slotted portion including a first segment with a first pattern of slotted openings and a second segment extending proximally relative the first segment with a second pattern of slotted openings different from the first pattern.

Abstract: The e-vaping device includes a first housing, a chamber defined within the first housing, a first structure and a second structure that interface with the chamber, the first structure is configured to accept at least one first-type consumable within the chamber and the second structure is configured to receive at least one second-type consumable within the chamber.

Abstract: An inhaler (10) has a main body for accommodating a medicament reservoir (84), a canister fire system for moving a canister (50) to release a dose in response to air flow, a cap housing (12) for enclosing the canister fire system and canister within an interior chamber defined by the main body (14) and a cap housing, wherein a lock system (250) is provided for locking the cap housing on the main body.

Abstract: The invention relates to a breathing device (1), comprising a mouthpiece (2) forming a breathing channel to form a connection between a first (3) end and a second (4) end of the mouthpiece (2). The first (3) end is configured for a user breathing into the mouthpiece through a breathing opening (5). An at least partly flexible rebreathing air chamber (6) is arranged in fluid communication with the second (4) end of the mouthpiece, thereby being in fluid connection with the breathing channel through the second end of the mouthpiece (2). The rebreathing air chamber is formed by at least partly flexible wall section(s). A wall member (7) is arranged at the second (4) end of the mouthpiece and/or attached to the rebreathing air chamber (6). The wall member (7) comprises one or more through-going openings (8) provided in the wall member (7) and/or in the breathing channel, allowing fluid communication between the rebreathing air chamber (6) and the surrounding atmosphere.